Unit Dose Packages, Compositions, And Treatment Regimens To Deliver Pro-Resolution Pathway Stimulators To Keratin Surfaces

Patent metadata

Field	Value
Publication number	US-2016303034-A1
Application number	US-201615099991-A
Country	US
Kind code	A1
Filing date	Apr 15, 2016
Priority date	Apr 16, 2015
Publication date	Oct 20, 2016
Grant date	—

Abstract

Ampoule containing a Pro-Resolution Pathway Stimulator, methods for making, and treating for skin having discrete areas of inflammation using ampoule composition containing Pro-Resolution Pathway Stimulator.

First claim

1 . A unit dose package containing a composition comprising at least one Pro-Resolution Pathway Stimulator.

2 . The unit dose package of claim 1 which is a capsule or a facial treatment mask.

3 . The unit dose package of claim 2 where the capsule is an ampoule.

4 . The unit dose package of claim 1 where the Pro-Resolution Pathway Stimulator is an Inflammatory Metabolite Inhibitor, a Pro-Resolving Activator, or mixtures thereof.

5 . The unit dose package of claim 4 wherein the Pro-Resolution Pathway Stimulator is a Pro-Resolving Activator.

6 . The unit dose package of claim 4 wherein the Pro-Resolution Pathway Stimulator is both an Inflammatory Metabolite Inhibitor and a Pro-Resolving Activator.

7 . The unit dose package of claim 2 wherein the capsule is made of gelatin.

8 . The unit dose package of claim 7 wherein the gelatin is a plant derived gelatin.

9 . The unit dose package of claim 8 wherein the plant derived gelatin is a hydrocolloid selected from carrageenan, seaweed, or mixtures thereof.

10 . The unit dose package of claim 8 wherein the gelatin comprises 1-25% gelatin, 1-60% starch, and 1-30% plasticizer.

11 . A method for making a unit dose package containing a composition comprising at least one Pro-Resolution Pathway Stimulator comprising the steps of:
(a) selecting an active ingredient; (b) quantifying:
(i) the inhibition in release of one or more Inflammatory Metabolites or Inflammatory Metabolite Markers from cells to which the active is exposed, and/or
(ii) the increase in release of one or more Pro-Resolving Lipid Mediators or Pro-Resolving Lipid Mediator Markers in cells exposed to the active,
(c) selecting the active that shows:
(i) a decrease in release of Inflammatory Metabolites or Inflammatory Metabolite Markers individually or in combination; and/or
(ii) an increase in release of Pro-Resolving Lipid Mediators or Pro-Resolving Lipid Mediator Markers individually or in combination
(d) formulating the active selected in (c) into a composition; and (e) packaging the composition of (e) into a unit dose package.

11 . The method of claim 11 where the unit dose package is a capsule.

12 . The method of claim 11 where the capsule is an ampoule.

13 . The method of claim 12 wherein the Pro-Resolution Pathway Stimulator is an Inflammatory Metabolite Inhibitor, a Pro-Resolving Activator or both.

14 . The method of claim 12 wherein the ampoule is made of gelatin.

15 . The method of claim 14 wherein the gelatin is derived from plants.

16 . The method of claim 15 wherein the gelatin is a hydrocolloid which is carrageenan, seaweed, or mixtures thereof.

17 . The method of claim 13 wherein the Pro-Resolution Pathway Stimulator is an Inflammatory Metabolite Inhibitor that causes a decrease in cellular concentration of Inflammatory Metabolites.

18 . The method of claim 13 wherein the Pro-Resolution Pathway Stimulator is a Pro-Resolving Activator.

19 . The method of claim 18 wherein the Pro-Resolving Activator stimulates an increase in cellular concentration of Pro-Resolution Lipid Mediators.

20 . The method of claim 19 wherein the Pro-Resolution Lipid Mediators are Resolvin, Protectin, Lipoxin, or Maresin.

21 . A method for treating skin that has discrete areas of inflammation or to inhibit skin inflammation by:
(a) formulating a composition containing at least one Pro-Resolution Pathway Stimulator, (b) packaging the composition into a package, (c) applying the contents of the package to the discrete areas of inflammation on the skin in need of such treatment.

22 . The method of claim 21 wherein the skin is treated with a skin care product prior to treating the discrete areas of inflammation on the skin.

23 . The method of claim 21 wherein the discrete areas of inflammation on the skin are first treated with the ampoule composition followed by application of a skin cream or lotion to the entire skin surface.

Assignees

• Elc Man Llc

Inventors

• Collins Donald
• Pernodet Nadine
• Fontanet Osvaldo

Classifications

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P17/00

  Drugs for dermatological disorders · CPC title

• A61K8/9711

  Phaeophycota or Phaeophyta [brown algae], e.g. Fucus · CPC title

• A61K8/9789

  Magnoliopsida [dicotyledons] · CPC title

• A61K8/347 Primary

  Phenols · CPC title